Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Debt to Equity (2016 - 2026)

Collegium Pharmaceutical has reported Debt to Equity over the past 11 years, most recently at $1.86 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 26.76% year-over-year to $1.86; the TTM value through Dec 2025 reached $1.86, down 26.76%, while the annual FY2025 figure was $1.86, 26.76% down from the prior year.
  • Debt to Equity for Q4 2025 was $1.86 at Collegium Pharmaceutical, down from $2.07 in the prior quarter.
  • Over five years, Debt to Equity peaked at $3.2 in Q1 2022 and troughed at $0.49 in Q3 2021.
  • A 5-year average of $2.09 and a median of $2.48 in 2023 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: plummeted 54.46% in 2021 and later skyrocketed 508.57% in 2022.
  • Year by year, Debt to Equity stood at $0.54 in 2021, then soared by 430.2% to $2.87 in 2022, then dropped by 27.9% to $2.07 in 2023, then rose by 22.22% to $2.53 in 2024, then decreased by 26.76% to $1.86 in 2025.
  • Business Quant data shows Debt to Equity for COLL at $1.86 in Q4 2025, $2.07 in Q3 2025, and $2.52 in Q2 2025.